Servier Breaks Ground of Servier Paris-Saclay Research Institute

Paris (France), 19 June 2019 - Servier, an independent international pharmaceutical company, has laid the foundation stone of its future Research Institute in the Paris-Saclay cluster. The new Servier Paris-Saclay Research Institute will house all of the Group's research activities located in France by 2022.

The ceremony, chaired by Olivier Laureau, President of Servier group, took place in the presence of Abdel-Kader Guerza, Sub-Prefect for Palaiseau, Cédric Villani, Deputy of Essonne, Jean-François Vigier, Mayor of Bures-sur-Yvette, Île-de-France Regional Councillor, and representing Valérie Pécesse, President of the Île-de-France Region, Michel Bournat, Mayor of Gif-sur-Yvette, President of the Paris-Saclay Combined District Council, Philippe Van de Maele, Managing Director of Paris-Saclay Public Development (EPAPS), and Jean-Michel Wilmotte, architect for the project.

"It is with great joy and pride to lay the foundation stone of the future Servier Paris-Saclay Research Institute, within this innovative and dynamic ecosystem. This milestone further exemplifies the Group’s ongoing commitment to the discovery of innovative therapeutic solutions for patients," said Olivier Laureau, President of Servier. "By combining the research activities of our four French sites into a single, unique, and state-of-the-art center in Paris-Saclay, the Servier group is continuing to support France whilst attracting researchers from around the world."

Paris-Saclay, one of the world’s top 8 innovation clusters

This benchmark project supported by the Paris-Saclay cluster resonates perfectly with the Servier group’s policy of open innovation via a strategy of dynamic partnerships. At its new Research Institute, the Servier group will work alongside other scientific organizations thus providing a natural opportunity for collaboration and potential innovation. Paris-Saclay is one of the world’s top 8 innovation clusters and is home to 40% of all industrial R&D in the Paris region.

Furthermore, the Servier group will be able to rely on the expertise of CentraleSupélec, the French Alternative Energies and Atomic Energy Commission (CEA), the French National Center for Scientific Research, Paris-Sud University, the Ecole Normale Supérieure and the Ecole Polytechnique, some of which have already been working with the Group for several years.

"The laying of the first stone of the new Servier Research Institute is an embodiment of the collaboration between the Paris-Saclay Public Development and the Servier group. We are delighted to welcome the Servier group to our cluster, whose presence will strengthen the potential for innovation and excellence of the Paris-Saclay site. The synergies that will be created between the major players, thanks to the Servier group’s presence, will make France an even more attractive prospect in terms of scientific and medical innovation," explained Philippe Van de Maele, Managing Director of Paris-Saclay Public Development (EPAPS).
Accelerating research for the benefit of patients

The Servier Group has nearly 2,900 employees working in research and development around the globe. The future Servier Paris-Saclay Research Institute will, at a single site, house 600 researchers who are currently spread across four locations in France (Croissy-sur-Seine, Suresnes, Orléans, and Gidy). By gathering its French research activities within a single research center, Servier will be able to accelerate the decision-making process, explore new ways of working, share knowledge more efficiently, disseminate best practices, and encourage partnerships.

A Group driven by innovation:

- 25% of brand-name drugs revenue invested in R&D each year
- 2,900 R&D employees around the world
- 600 researchers in France
- 33 research projects (January 31, 2019)
- 33 drug candidates, including 23 new molecular entities
- + 50 partnerships worldwide
- Research focused on 5 therapeutic areas: cardiovascular diseases, immune-mediated inflammatory diseases, neurodegenerative diseases, cancers and diabetes

This research dynamic will be boosted even further by the creation of a one-of-a-kind incubator in France, at the Research Institute. It will be home to the most innovative start-ups in the medical sector, which will be able not only to develop their projects independently, but also to share their expertise with Servier teams to make the collaboration even more dynamic. Covering 1,850 m², this innovation hub will offer 80 workstations for start-ups, including fully-equipped laboratories, collaborative areas, and office space.

The new facility will also speed up research efforts, especially in oncology which is one of Servier’s strategic priorities and a key branch of its therapeutic research. Currently, 700 employees in 50 countries are working to develop innovative oncology therapeutic solutions. Over the next 2 years, oncology will account for half of the Group’s R&D budget. Five cancer treatments are available, so far, and the Servier group is working to develop 12 drug candidates. Servier has signed 21 partnership agreements with academic institutions, as well as industrial partners and biotech companies in this therapeutic area.

“This new Research Institute is a tremendous tool that will make the Servier group even more effective at addressing the unmet needs of patients. By uniting our experts at what will become the Group’s largest research center, we can ensure an even faster exploration of new therapeutic pathways, whilst benefiting from the cutting-edge knowledge and experience offered by one of the most dynamic research environments available, where creativity, innovation, and entrepreneurship are both encouraged and valued,” explains Claude Bertrand, Executive Vice President R&D at Servier.

---

1 Excluding generics
A responsible Research Institute

Servier Paris-Saclay Research Institute key figures:

- £290 million investment
- 45,000 m²
- Work to be completed in 2022
- 5,000 m² of gardens and nearly 9,000 m² of green roofs
- Capacity for up to 800 employees
- 70 research sectors working within the Institute

"This harmonious and highly ambitious project is designed around green spaces and a central harnessing element, a symbol of the unity and dynamic nature of the Servier group. This crystalline circular structure interacts with slender sculpted spaces to promote conversation, create synergies, and drive real innovation", said Jean-Michel Wilmotte, architect for the project.

Staying true to French roots

By housing its new Research Institute in Saclay, the Servier group, currently the second largest French pharmaceutical company employing 5,000 people in France, has reiterated its desire to bolster the worldwide influence of French research. The added value that this investment will create for the country reflects the Group's conscious decision to remain strongly rooted in France, where it has two production plants and its headquarters.

Find more information at www.servier.com

About Servier:
Servier is an international pharmaceutical laboratory run by a Foundation, with its headquarters in Suresnes in France. With a solid international footing in 149 countries and revenues of €4.2 billion in 2018, Servier employs 22,000 people around the globe. Wholly independent, the Group reinvests 25% of its income (excluding generics) into Research and Development and ploughs all its profit into its growth. The Group attributes its growth to an incessant quest for innovation in five fields of excellence: cardiovascular diseases, immune-mediated inflammatory diseases, neurodegenerative diseases, cancers and diabetes, as well as its development of high-quality generics. Servier also offers e-health solutions in addition to its medicinal products.
For more information visit: www.servier.com.

Press contacts Servier Group:
Sonia Marques: sonia.marques@servier.com – Tel. +33 (0)1 5572 4021 / +33 (0)7 8428 7613
Jean-Clément Vergeau: jean-clement.vergeau@servier.com – Tel. +33 (0)1 5572 4616 / +33 (0)6 7956 7596
Karine Bousseau: karine.bousseau@servier.com – Tel. +33 (0)1 5572 6037 / +33 (0)6 4992 1605

Follow Servier on social media:
About EPA Paris-Saclay:
The Etablissement public d’aménagement Paris-Saclay promotes and coordinates the development of the scientific and technological center of the Saclay plateau, as well as its international economic influence. It is a developer of cooperative development zones operating within the scope of the National Interest Operation. Paris-Saclay is a major site for development and innovation based on: an academic center structured around the University of Paris-Saclay and the Institut Polytechnique de Paris, representing an exceptional science hub in terms of its scale, disciplinary diversity, and level of excellence; an innovative dynamic at work in several strategic sectors to promote growth and job creation; existing urban centers and a protected natural agricultural area accompanied by innovative services and new technologies; line 18 of the Greater Paris automated metro system which will link Orly to Saclay in 2027 and then to Versailles in 2030.

Press contacts EPA Paris-Saclay:
Jérôme Chiaramonti: jerome.chiaramonti@oin-paris-saclay.fr – Tel. +33 (0)1 64 54 26 78
Rachel Brunella: rachel.brunella@manifeste.fr – Tel. +33 (0)1 55 34 99 84

About Wilmotte & Associés:
Wilmotte & Associés is an international firm of architects founded in 1975 by the architect, urban planner, and designer Jean-Michel Wilmotte, member of the Académie des Beaux-Arts. Along with its design studio Wilmotte & Industries, it currently employs 270 people of 25 nationalities in France, the UK, Italy, and South Korea, working on over 100 projects in 28 countries with a strong focus on the luxury, hospitality, cultural, and service industries. A winner of several international awards, W&A is one of the world’s 100 largest architectural firms, according to a study by British magazine Building Design.

Wilmotte & Associés press office:
Julien Commault: julien.commault@wilmotte.fr – Tel. +33 (0)1 5302 2222